drugset
drugset / Trial / NCT02788058

A Study of Hypofractionated Radiotherapy for Limited Metastatic NSCLC Harboring Sensitizing EGFR Mutations After First Line TKI Therapy

NCT02788058 ↗

Phase 2 Unknown 76 enrolled First People's Hospital of Hangzhou
RandomizedParallel-groupOpen-labelTreatment

Summary

To evaluate the efficacy and toxicity of patients treated with hypofractionated radiotherapy for limited metastatic NSCLC harboring sensitizing EGFR mutations after first line TKI therapy. An exploratory biomarker analysis in blood and tumor samples is also planned.

Timeline

Start
2016-05
Primary completion
2021-05
Completion
2022-05

Drugs

EvaluationDrugModalityDoseRoute
Background Erlotinib Small molecule 150 mg Oral
Background Gefitinib Small molecule 250 mg Oral
Background Icotinib Small molecule 125 mg Oral

Indications

lung adenocarcinoma